SURVIVAL BENEFIT ASSOCIATED WITH FLUOROPYRIMIDINES, PLATINUM AGENTS, TAXANES, AND IRINOTECAN DURING ALL LINES OF TREATMENT IN PATIENTS WITH ADVANCED GASTRIC CANCER

被引：0
|
作者：
Shitara, K. [1 ]
Matsuo, K. [2 ]
Takahari, D.
Yokota, T. [1 ]
Ura, T.
Ito, S.
Sawaki, A.
Tajika, M.
Kawai, H.
Muro, K.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Aichi Canc Ctr Res Inst, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [31] Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer
    Du, Rui
    Hu, Pingping
    Liu, Qiqi
    Zhang, Jingxin
    Deng, Guodong
    Hu, Dan
    Zhang, Jiandong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2018, 17
  • [32] Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis
    Eom, Bang Wool
    Kim, Sohee
    Kim, Ja Yeon
    Yoon, Hong Man
    Kim, Mi-Jung
    Nam, Byung-Ho
    Kim, Young-Woo
    Park, Young-lee
    Park, Sook Ryun
    Ryu, Keun Won
    JOURNAL OF GASTRIC CANCER, 2018, 18 (01) : 69 - 81
  • [33] Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-Reply
    Shitara, Kohei
    Tabernero, Josep
    JAMA ONCOLOGY, 2021, 7 (04) : 633 - 633
  • [34] Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 metastatic colon cancer patients.
    Hanna, Nader
    Woods, Corinne
    Zheng, Zhiyuan
    Onukwugha, Ebere
    Seal, Brian S.
    Mullins, C. Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] SNP Array 6.0 Analysis in Advanced Gastric Cancer Patients Treated With 5-FU and Platinum or Irinotecan Based Chemoradiation
    Grimminger, Peter P.
    Maus, Martin K.
    Schumacher, Frederick
    Metzger, Ralf
    Brabender, Jan
    Hoelscher, Arnulf H.
    Lenz, Heinz-Joseph
    GASTROENTEROLOGY, 2012, 142 (05) : S1089 - S1089
  • [36] A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane
    Hara, Hiroki
    Mizukami, Takuro
    Minashi, Keiko
    Nishina, Tomohiro
    Takahashi, Naoki
    Amanuma, Yusuke
    Nakasha, Akio
    Takahashi, Masaki
    Nakajima, Takako Eguchi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [37] Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
    Kato, K.
    Masuishi, T.
    Fushiki, K.
    Nakano, S.
    Kawamoto, Y.
    Narita, Y.
    Tsushima, T.
    Harada, K.
    Kadowaki, S.
    Todaka, A.
    Yuki, S.
    Tajika, M.
    Machida, N.
    Komatsu, Y.
    Yasui, H.
    Muro, K.
    Kawakami, T.
    ESMO OPEN, 2021, 6 (04)
  • [38] Outcomes of 596 Advanced Gastric Cancer Patients with Different Numbers of Chemotherapy Lines: The More Chemotherapy Lines, the Better Survival
    Sun, Li
    Wang, Huijun
    Liu, Zhen
    Meng, Ying
    Qiu, Meiqing
    Ju, Yafei
    Zhang, Shu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10631 - 10638
  • [39] Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer
    Jung, Hyun Ae
    Kim, Hyun-Jun
    Maeng, Chi Hoon
    Park, Se Hoon
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Um, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2015, 47 (01): : 72 - 77
  • [40] Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer
    Takayoshi, Kotoe
    Uchino, Keita
    Nakano, Masahiro
    Ikejiri, Koji
    Baba, Eishi
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2017, 69 (03): : 408 - 415
12345